ArticleDiabetes spectrum : a publication of the American Diabetes Association2025
System Failure in Type 1 Diabetes: What Stakeholders Need to Know to Expedite Therapeutic Options.
Article in Diabetes spectrum : a publication of the American Diabetes Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There has been a systemic failure in type 1 diabetes. Regulatory barriers and clinical trial design challenges discourage development of new type 1 diabetes therapies and can compromise the potential for securing approval of new treatments. As a result, there continues to be a pervasive unmet need for those living with type 1 diabetes, resulting in long-term complications, extreme disease management burdens, and psychosocial consequences. People with type 1 diabetes continue to make multiple daily decisions about dosing insulin, a drug that can kill with a single mistake and that at best only manages symptoms without changing the underlying progression of the disease. Furthermore, beyond regulatory challenges, gaps in health care professionals' (HCPs') knowledge and understanding of the disease affect quality of care. The goal of this article is to educate stakeholders on the extent of this systemic failure and to encourage consideration and dialogue among industry, regulatory agencies, patients, and HCPs to expedite approval of breakthrough therapies that fundamentally change the equation in type 1 diabetes.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.